ArticleScientific reports2016
REAC technology modifies pathological neuroinflammation and motor behaviour in an Alzheimer's disease mouse model.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Endogenous Bioelectrical Modulation of Longevity-Associated and Inflammatory Signaling Pathways in Human Dermal Fibroblasts Following the REAC ACT-IBZ Protocol.Life (Basel, Switzerland) · 2026Article
- REAC RGN-AR treatment modulates adipogenic differentiation in adipose tissue-derived stem cells.Scientific reports · 2026Article
- Targeted Endogenous Bioelectric Modulation in Autism Spectrum Disorder: Real-World Clinical Outcomes of the REAC BWO Neurodevelopment-Autism Protocol.Journal of clinical medicine · 2025Article
- Article
- Acute targeting of N-terminal tau protein has long-lasting beneficial effects in Tg2576 APP/Aβ mouse model by reducing cognitive impairment, cerebral Aβ-amyloidosis, synaptic remodeling and microgliosis later in life.Acta neuropathologica communications · 2025Article
- Article
- Article
- Article
- Article
- Article
- Effects of Combining Music Therapy, Light Therapy, and Chromotherapy in the Treatment of Chronic Pain Patients: A Pilot Study.Evidence-based complementary and alternative medicine : eCAM · 2024Article
- REAC Neurobiological Modulation as a Precision Medicine Treatment for Fibromyalgia.Journal of personalized medicine · 2023Article
- Effects of the radio electric asymmetric conveyer (REAC) on motor disorders: An integrative review.Frontiers in medical technology · 2023Review
- Antisenescence effect of REAC biomodulation to counteract the evolution of myelodysplastic syndrome.Physiological research · 2022Article
- Article
- REAC neurobiological treatments in acute post-traumatic knee medial collateral ligament lesion.Heliyon · 2020Article
- Radio Electric Asymmetric Conveyer Neurobiological Treatments in Non-Specific Neck Pain: A Retrospective Study.Journal of pain research · 2020Article
- Radio electric asymmetric conveyer neuromodulation in depression, anxiety, and stress.Neuropsychiatric disease and treatment · 2019Article
- Physical stimulation by REAC and BMP4/WNT-1 inhibitor synergistically enhance cardiogenic commitment in iPSCs.PloS one · 2019Article
- Radio Electric Asymmetric Conveyer Technology Modulates Neuroinflammation in a Mouse Model of Neurodegeneration.Neuroscience bulletin · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The search for new therapeutic approaches to Alzheimer disease (AD) is a major goal in medicine and society, also due to the impressive economic and social costs of this disease. In this scenario, biotechnologies play an important role. Here, it is demonstrated that the Radio Electric Asymmetric Conveyer (REAC), an innovative technology platform for neuro- and bio-modulation, used according to the neuro-regenerative protocol (RGN-N), significantly increases astroglial reaction around the amyloid plaques in an AD mouse model, as evaluated by GFAP-immunoreactivity, and reduces microglia-associated neuroinflammation markers, as evaluated by Iba1-immunoreactivity and mRNA expression level of inflammatory cytokines TREM. IL1beta, iNOS and MRC1 were not affected neither by the genotype or by REAC RGN-N treatment. Also observed was an increase in locomotion in treated animals. The study was performed in 24-month-old male Tg2576 mice and age-matching wild-type animals, tested for Y-maze, contextual fear conditioning and locomotion immediately after the end of a specific REAC treatment administered for 15 hours/day for 15 days. These results demonstrated that REAC RGN-N treatment modifies pathological neuroinflammation, and mitigates part of the complex motor behaviour alterations observed in very old Tg2576 mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.